Characterization of the promoter region of the plasminogen activator inhibitor 2 gene

Relationship between plasma levels of components of the fibrinolytic system and acute‐phase reactants in patients with uterine malignancies

“…In contrast to findings in other malignant diseases [12,16,38,39], PA1 activity levels were unchanged in the two groups of patients studied. This lack of increase in PA1 was independent from the type as well as from the grade or stage of the carcinoma.…”

“…PA1 has been described as an acute-phase protein in patients with septicaemia [26], extracorporeal circulation [25], the postoperative phase [22-241 and in patients with malignant tumours [16,39]. However, the malignant tumours in those studies were neither specified depending on the organ, tumour stage nor histological type [12,16,38,39]. Therefore, it is difficult to compare those data despite the fact that different laboratory standards and selection of subpopulations of patients might influence the results.…”

“…However, the source of plasma u-PA is still unclear. Increased PA1 activity on the other hand was also observed in patients with malignant tumours [16], cardiovascular or thromboembolic diseases [ 17-2 I], in the postoperative phase [22-241, with hepatic insufficiency [25], after trauma, after extracorporeal circulation [25] and with septicaemia [26] and thus PA1 behaves like an acute-phase reactant [27].…”